Stockreport

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis Inc.  (ALMS) 
PDF – Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to a [Read more]